Physician profile
Scott Kurtzman
NPI 1457357451
$1,391.59
in general payments reported to CMS, 2019-2025
35 companies · $29.63 in 2025
The $29.63 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $197 · 2021: $205 · 2022: $249 · 2023: $132 · 2024: $75.44 · 2025: $29.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $131.94 | 2020-2021 | |
| Csl Behring | $107.25 | 2021-2025 | Kcentra |
| E.R. Squibb & Sons, L.L.C. | $106.98 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $67.37 | 2019-2021 | |
| Medical Device Business Services, INC. | $66.42 | 2019 | |
| Z-Medica, LLC | $65.14 | 2019 | |
| Medtronic, INC. | $60.01 | 2021-2022 | |
| Heron Therapeutics, INC. | $55.61 | 2021-2023 | Zynrelef |
| Bard Access Systems, INC. | $55.54 | 2019 | |
| Smith+Nephew, INC. | $53.84 | 2019-2022 | |
| Genentech USA, INC. | $46.12 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $45.99 | 2022-2023 | Gvoke Hypopen |
| Portola Pharmaceuticals, LLC | $40.91 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.78 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.48 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $34.44 | 2023 | |
| Boston Scientific Corporation | $31.25 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.31 | 2022 | |
| Integra Lifesciences Corporation | $24.62 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Tela Bio, INC. | $22.29 | 2021 | |
| Cequr Corporation | $22.22 | 2022 | |
| Corcept Therapeutics | $22.05 | 2019 | |
| Ambu INC. | $20.93 | 2024 | |
| Antares Pharma, INC. | $20.00 | 2023 | Nocdurna, Tlando, Xyosted |
| Amneal Pharmaceuticals LLC | $19.59 | 2022 | |
| Lemaitre Vascular, INC. | $19.20 | 2021 | |
| Myriad Genetic Laboratories, INC. | $18.46 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.82 | 2019 | |
| Convatec INC. | $17.68 | 2023 | |
| Lilly USA, LLC | $16.31 | 2022 | |
| Abbvie INC. | $16.17 | 2019 | |
| Endo Pharmaceuticals INC. | $15.84 | 2019 | |
| Janssen Biotech, INC. | $15.66 | 2019 | |
| Vioptix INC | $15.16 | 2023 | |
| Aytu Biopharma, INC. | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kurtzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.